Iterum Therapeutics Plc2024财年第三财季实现净利润-6.09百万美元，同比减少56.96%

市场透视11-23

11月23日，Iterum Therapeutics Plc（ITRM.US）公布财报，公告显示公司2024财年第三财季净利润为-6.09百万美元，同比减少56.96%；其中营业收入为0.00美元，每股基本收益为-0.30美元。从资产负债表来看，Iterum Therapeutics Plc（ITRM.US）总负债27.43百万美元，其中短期债务13.98百万美元，资产负债比为0.59，流动比率为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485829873?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-23 00:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2485829873","market":"us","top_or_hot":-1,"title":"Iterum Therapeutics Plc2024财年第三财季实现净利润-6.09百万美元，同比减少56.96%","media":"市场透视","content":"<div>\n<p>11月23日，Iterum Therapeutics Plc（ITRM.US）公布财报，公告显示公司2024财年第三财季净利润为-6.09百万美元，同比减少56.96%；其中营业收入为0.00美元，每股基本收益为-0.30美元。从资产负债表来看，Iterum Therapeutics Plc（ITRM.US）总负债27.43百万美元，其中短期债务13.98百万美元，资产负债比为0.59，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000253abd7b8fe&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iterum Therapeutics Plc2024财年第三财季实现净利润-6.09百万美元，同比减少56.96%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIterum Therapeutics Plc2024财年第三财季实现净利润-6.09百万美元，同比减少56.96%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-23 00:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000253abd7b8fe&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月23日，Iterum Therapeutics Plc（ITRM.US）公布财报，公告显示公司2024财年第三财季净利润为-6.09百万美元，同比减少56.96%；其中营业收入为0.00美元，每股基本收益为-0.30美元。从资产负债表来看，Iterum Therapeutics Plc（ITRM.US）总负债27.43百万美元，其中短期债务13.98百万美元，资产负债比为0.59，流动比率为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000253abd7b8fe&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000253abd7b8fe&s=b","article_id":"2485829873","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123000253abd7b8fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2485829873","pubTimestamp":1732291339,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月23日，Iterum Therapeutics Plc公布财报，公告显示公司2024财年第三财季净利润为-6.09百万美元，同比减少56.96%；其中营业收入为0.00美元，每股基本收益为-0.30美元。从资产负债表来看，Iterum Therapeutics Plc总负债27.43百万美元，其中短期债务13.98百万美元，资产负债比为0.59，流动比率为0.85。机构评级：截至2024年11月23日，当前有2家机构对Iterum Therapeutics Plc目标价做出预测，其中目标均价为7.50美元，其中最低目标价为5.00美元，最高目标价为10.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","ITRM":"Iterum Therapeutics Plc"},"translate_title":"Iterum Therapeutics Plc achieved net profits of-US $6.09 million in the third fiscal quarter of fiscal year 2024, a year-on-year decrease of 56.96%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITRM":1,"LENZ":1},"content_text":"11月23日，Iterum Therapeutics Plc（ITRM.US）公布财报，公告显示公司2024财年第三财季净利润为-6.09百万美元，同比减少56.96%；其中营业收入为0.00美元，每股基本收益为-0.30美元。从资产负债表来看，Iterum Therapeutics Plc（ITRM.US）总负债27.43百万美元，其中短期债务13.98百万美元，资产负债比为0.59，流动比率为0.85。机构评级：截至2024年11月23日，当前有2家机构对Iterum Therapeutics Plc目标价做出预测，其中目标均价为7.50美元，其中最低目标价为5.00美元，最高目标价为10.00美元。公司简介：Iterum Therapeutics PLC 是一家临床阶段的制药公司。该公司致力于开发和商业化苏洛培南，成为全球首个且唯一的口服和静脉注射品牌青霉素类药物。其苏洛培南项目有潜力解决抗生素耐药性问题和现有药物的毒性限制。该公司作为单一业务部门运营，其业务领域是开发和商业化治疗耐药细菌感染的药物。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485829873"}